Orellanine

Small molecule

Orellanine is one of 9 small molecule programs targeting Papillary Renal Cell Carcinoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Papillary Renal Cell CarcinomaActive, not recruiting

Papillary Renal Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Papillary Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

1 2

Cabometyx

Bristol-Myers Squibb

Phase 2

—3

Inlyta

PPrism Pharmaceuticals

Phase 2

1 4

Glucophage

EMD Serono

Phase 2

1 5

Caprelsa

GGenzyme, a Sanofi Company

Phase 2

1 6

Sasanlimab

Pfizer

Phase 2

1 7

AZD6094

AstraZeneca

Phase 2

1 8

Palbocicilib

NNational Cancer Institute (NCI)

Phase 2

1 9

Orellanine

OOncorena AB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Papillary Renal Cell Carcinoma

NCT05287945

Clinical

Trials by Indication[1]

Papillary Renal Cell Carcinoma1 trial

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Recruiting·OOncorena AB·Phase 1/2·NCT05287945·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Orellanine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orellanine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orellanine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oncorena AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: OOncorena AB

Orellanine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Papillary Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News